SGCG and COVID-19: Interestingly, we observed that mild vs critical COVID-19, not only differed quantitatively in terms of the number of T-cells exhibiting good effector function, but also qualitatively, in terms of consistently lower activation levels of the type 1 and II IFN (anti-viral) signaling pathways (amongst several other pathways).